Welcome to the international HTA database

Showing [16524 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Bevacizumab (Avastin) for triple negative adjuvant breast cancer; in combination with taxane and/or anthracycline chemotherapy
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Sodium valproate (Episenta®)
2011	NIHR Health Technology Assessment programme	The clinical effectiveness and safety of prophylactic retinal interventions to reduce the risk of retinal detachment and subsequent vision loss in adults and children with Stickler syndrome: a systematic review
2011	NIHR Health Technology Assessment programme	A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Amisulpride for adults with refractory schizophrenia: a review of the clinical effectiveness and safety
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Collagenase Clostridium histolyticum (Xiapex®)
2011	NIHR Health Technology Assessment programme	MAVARIC - a comparison of automation-assisted and manual cervical screening: a randomised controlled trial
2011	NIHR Health Technology Assessment programme	Prucalopride for the treatment of chronic constipation in women in whom laxatives fail to provide adequate relief
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	The association between obesity, aboriginal or indigenous people, indian or alaskan natives living in North America and residence in remote locations and severe outcomes with seasonal and pandemic influenza: a review of the clinical evidence
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tenofovir disoproxil fumarate (Viread®)
2011	Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR)	Criteria for appropriate use of FDG-PET in breast cancer
2011	NIHR Health Technology Assessment programme	Growth monitoring for short stature: update of a systematic review and economic model
2011	Medical Advisory Secretariat (MAS)	Endovascular radiofrequency ablation for varicose veins: an evidence-based analysis
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Preoperative skin antiseptic preparations and application techniques for preventing surgical site infections: a systematic review of the clinical evidence and guidelines
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Histamine dihydrochloride (Ceplene®)
2011	NIHR Health Technology Assessment programme	Processes in recruitment to randomised controlled trials of medicines for children (RECRUIT): a qualitative study
2011	NIHR Health Technology Assessment programme	Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis
2011	Medical Advisory Secretariat (MAS)	Diurnal tension curves for assessing the development or progression of glaucoma: an evidence-based analysis
2011	Medical Advisory Secretariat (MAS)	Constraint induced movement therapy for rehabilitation of arm dysfunction after stroke in adults
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Cetuximab (Erbitux) in combination with oxaliplatin, leucovorin and fluorouracil for colorectal cancer - adjuvant
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Sunitinib (Sutent®)
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Cetuximab (Erbitux) in combination with capecitabine and cisplatin for advanced or metastatic gastric cancer – first line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ferric carboxymaltose (Ferinject®)
2011	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation
2011	NIHR Health Technology Assessment programme	Golimumab for the treatment of psoriatic arthritis
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Dasatinib (Sprycel) for prostate cancer – in combination with docetaxel
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valganciclovir (Valcyte®) tablets
2011	NIHR Horizon Scanning Centre (NIHR HSC)	EC145 for folate receptor positive ovarian cancer
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valganciclovir (Valcyte®) powder for oral solution
2011	National Institute for Health and Care Excellence (NICE)	moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment. NICE medical technologies guidance 2
2011	NIHR Health Technology Assessment programme	Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Erlotinib (Tarceva) in combination with sorafenib (Nexavar) for unresectable, advanced or metastatic hepatocellular carcinoma – first line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Capecitabine (Xeloda®)
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Heat-activated liposome encapsulated doxorubicin (ThermoDox) for hepatocellular carcinoma – first line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tacrolimus (Advagraf®)
2011	NIHR Health Technology Assessment programme	Development and evaluation by a cluster randomised trial of a psychosocial intervention in children and teenagers experiencing diabetes: the DEPICTED study
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Ipilimumab (Yervoy) for prostate cancer – second line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Fentanyl (PecFent®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Adjunctive devices for patients with acute coronary syndrome undergoing percutaneous coronary intervention
2011	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Masitinib with gemcitabine for advanced or metastatic pancreatic cancer
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Darunavir (Prezista®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Effectiveness of early diagnosis, prevention, and treatment of clostridium difficile infection
2011	Scottish Health Technologies Group (SHTG)	What is the clinical and cost effectiveness of the ThinPrep imager® (HologicTM, Inc) for assisted cervical cytology compared with manual reading of liquid based cytology slides?
2011	NIHR Health Technology Assessment programme	A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease
2011	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of management strategies for sciatica: systematic review and economic model
2011	NIHR Health Technology Assessment programme	Evaluating meta-ethnography: systematic analysis and synthesis of qualitative research
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Tests for early diagnosis of sepsis
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Paclitaxel (Paclical) for epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer – second or third line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valsartan (Diovan®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of the use of brachytherapy to treat breast cancer
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines for management of sepsis
2011	Belgian Health Care Knowledge Centre (KCE)	Transcatheter aortic valve implantation (TAVI): an updated health technology assessment
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Caris Target Now™ molecular profiling service for solid malignant tumours
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Filgrastim (Nivestim®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review
2011	Scottish Health Technologies Group (SHTG)	What is the evidence base for the use of orthopaedic spinal surgery for mechanical low back pain or degenerative spondylolisthesis?
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Impact of retracted articles on the evidence base for hydroxyethyl starch
2011	Agency for Healthcare Research and Quality (AHRQ)	Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Tunneled vs. non-tunneled catheters for acute hemodialysis
2011	Agency for Healthcare Research and Quality (AHRQ)	Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and direct renin inhibitors for treating essential hypertension: an update
2011	Scottish Health Technologies Group (SHTG)	Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults. This evidence note updates evidence note 33 published in March 2011
2011	National Institute for Health and Care Excellence (NICE)	Ambulight PDT for the treatment of non-melanoma skin cancer. NICE medical technologies guidance 6
2011	NIHR Health Technology Assessment programme	Identification of risk factors by systematic review and development of risk-adjusted models for surgical site infection
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Active management and treatment of postpartum hemorrhage
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Disinvestment. Overview of disinvestment experiences and challenges in selected countries
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Dalcetrapib for the prevention of cardiovascular events
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of long-term ventricular assist devices (VADs) as a bridge-to-transplant in adults
2011	National Institute for Health and Care Excellence (NICE)	The MIST Therapy system for the promotion of wound healing. NICE medical technologies guidance 5
2011	NIHR Health Technology Assessment programme	A randomised controlled trial of post-operative radiotherapy following breast-conserving surgery in a minimum-risk population. Quality of life at 5 years in the PRIME trial
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Risk factors for hospital readmission
2011	HAYES, Inc.	Acticoat (Smith&Nephew Inc.) for Burn Wounds
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Eribulin (Halaven) as third- or late- line mono-therapy for advanced/metastatic breast cancer
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Edoxaban tosylate for prevention of stroke and systemic embolic events in non-valvular atrial fibrillation
2011	Scottish Health Technologies Group (SHTG)	Is radiofrequency ablation treatment a clinically and cost effective treatment to be offered to people with renal cancer in NHSScotland?
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Femoral closure devices for cardiac catheterization
2011	NIHR Horizon Scanning Centre (NIHR HSC)	HHLivC (Human Heterologous Liver Cells) for urea cycle disorders
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Transradial access for cardiac catheterization
2011	HAYES, Inc.	Antibacterial suture for prevention of infection
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines for verifying Dobbhoff tube placement
2011	NIHR Horizon Scanning Centre (NIHR HSC)	IRay™ for wet age related macular degeneration
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Erlotinib (Tarceva) in combination with sorafenib (Nexavar) for unresectable, advanced or metastatic hepatocellular carcinoma – first line
2011	HAYES, Inc.	Bipolar plasmakinetic electrovaporization for benign prostatic hyperplasia (BPH)
2011	NIHR Horizon Scanning Centre (NIHR HSC)	ThromboLUX™ for determining platelet quality
2011	NIHR Health Technology Assessment programme	Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Rituximab (MabThera) for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
2011	NIHR Health Technology Assessment programme	The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation
2011	Adelaide Health Technology Assessment (AHTA)	Prevention, identification and management of foot complications in diabetes: technical report
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Odanacatib for post-menopausal osteoporosis – first or second line
2011	NIHR Health Technology Assessment programme	Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
2011	Norwegian Knowledge Centre for the Health Services (NOKC)	Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Tocilizumab (RoACTEMRA) for early rheumatoid arthritis not treated with methotrexate – first line
2011	NIHR Horizon Scanning Centre (NIHR HSC)	VEGF trap-eye (Eylea) for macular oedema secondary to central retinal vein occlusion - first line
2011	NIHR Health Technology Assessment programme	Bone-anchored hearing aids (BAHAs) for people who are bilaterally deaf: a systematic review and economic evaluation
2011	HAYES, Inc.	Endoscopic cyclophotocoagulation for glaucoma
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Trabectedin (Yondelis) for advanced and/or metastatic translocation-related sarcomas - first line